TITLE

Atenolol use after noncardiac surgery in cardiac patients

AUTHOR(S)
Andolsek, Kathryn M.
PUB. DATE
May 1997
SOURCE
American Family Physician;5/1/1997, Vol. 55 Issue 6, p2281
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents the randomized, double blind and placebo controlled trial performed by the Mangano and colleagues to evaluate the effect of atenolol on overall survival and cardiovascular morbidity in patients undergoing elective noncardiac surgery. Data and method used in the study; Survival rates of patients treated with Atenolol; Conclusions.
ACCESSION #
9706110029

Tags: ATENOLOL;  ATENOLOL -- Therapeutic use;  CARDIOVASCULAR system -- Diseases -- Treatment;  DRUGS -- Effectiveness

 

Related Articles

  • Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. Goyal, Ramesh K.; Bhadada, Shraddha V. // Canadian Journal of Physiology & Pharmacology;Aug2007, Vol. 85 Issue 8, p831 

    Recently, various clinical studies have indicated that lipophilic �-blockers reduce the coronary mortality in diabetic patients; however, systematic studies have not been reported. The objective of the present investigation was to compare the effects of chronic treatment with metoprolol and...

  • Would a polypill be beneficial in UK practice? McCormack, Terry // GP: General Practitioner;6/12/2009, p30 

    In this article the author discusses a debate about the potential of a polypill in reducing cardiovascular risk. The author notes that the polypill has varied on some ingredients as beneficial to reduce cardiovascular risk, but includes 12.5mg hydrochlorothiazide, 50mg atenolol, 5mg ramipril,...

  • Drug cuts death rates after surgery in half. Ferraro, Julia // RN;Apr97, Vol. 60 Issue 4, p17 

    Presents the results of a study on the effect of atenolol on patients' mortality after noncardiac surgery. Death rate of patients who took atenolol after a noncardiac surgery; Conclusion on the advantage of atenolol.

  • Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Deacon, S.P.; Karunanayake, A.; Barnett, D. // British Medical Journal;11/12/1977, Vol. 2 Issue 6097, p1255 

    Examines the metabolic effects of propranolol, acebutolol and atenolol on diabetics. Effects of the drugs; Therapeutic uses of the drugs; Safety of the drugs over pro-selective drugs in treating patients with diabetes.

  • Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Deacon, S.P.; Barnett, D. // British Medical Journal;7/31/1976, Vol. 2 Issue 6030, p272 

    Investigates the use of atenolol during insulin-induced hypoglycaemia. Effects of atenolol on pulse rate, sweating and blood glucose levels; Comparison of atenolol with propranolol; Safety of atenolol for use in patients receiving insulin.

  • Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Day, J.L.; Simpson, N.; Metcalfe, J.; Page, R.L. // British Medical Journal;1/13/1979, Vol. 1 Issue 6156, p77 

    Examines the metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Observation on the increase of basal plasma triglyceride concentration; Description on the changes in triglyceride concentration; Decrease of basal free fatty acid concentrations.

  • Atenolol and bendrofluazide in hypertension. Petrie, J.C.; Galloway, D.B.; Webster, J.; Simpson, W.T.; Lewis, J.A. // British Medical Journal;10/18/1975, Vol. 4 Issue 5989, p133 

    Examines the efficacy of atenolol and bendrofluazide in treating hypertension. Reduction in all blood pressure levels; Absence of significant postural or postexercise hypotension; Effect of the drug on the hematological or biochemical indices.

  • Rx for deaths after surgery. Podolsky, Doug; Beddingfield, Katherine T. // U.S. News & World Report;12/16/96, Vol. 121 Issue 24, p75 

    Discusses the benefits of administering atenolol during hospitalization following heart surgery. The reduction of risk of death for up to two years following the operation; The report by Dennis Mangano in `The New England Journal of Medicine.'

  • Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy. Rembold, Christopher M. // ACP Journal Club;Mar/Apr2003, Vol. 138 Issue 2, p37 

    Compares the effectiveness of losartan-based with atenolol-based therapy in patients with isolated systolic hypertension and left ventricular hypertrophy. Description of the patients in the study; Goal of antihypertensive therapy; Details of the study conducted by the Medical Research Council...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics